Form 4: Maze Therapeutics Officer Sells Stock Post-Option Exercise

Maze Therapeutics' CSBO Atul Dandekar reported exercising stock options and selling 7,500 shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Atul Dandekar, Chief Strategy and Business Officer (CSBO) of Maze Therapeutics, Inc., reported transactions on January 29, 2026.
• Exercised 7,500 stock options at an exercise price of $10.42 per share.
• Sold a total of 7,500 shares of common stock in multiple transactions on the same day.
• The sales occurred at weighted average prices of $43.1844, $44.0419, and $45.008 per share.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025.
• Following these transactions, Atul Dandekar directly beneficially owns 10,503 shares of common stock and 66,643 derivative securities (stock options).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While insider selling can sometimes be a negative signal, the transactions were pre-planned under a Rule 10b5-1 plan, mitigating concerns of opportunistic selling and representing a routine compensation event.

Positives

• The officer realized a significant profit by exercising options at $10.42 and selling the shares at prices ranging from $42.49 to $45.53.
• The transactions were executed under a Rule 10b5-1 trading plan, indicating pre-planned sales rather than opportunistic selling based on new, non-public information.

Negatives

• Insider selling, even if pre-planned, can sometimes be perceived by the market as a lack of confidence, although the 10b5-1 plan mitigates this concern.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales, are closely watched by investors for signals about management's confidence in the company's future prospects. While sales under a 10b5-1 plan are pre-scheduled and less indicative of immediate sentiment, the volume and price points are still relevant for market analysis within the biotechnology sector.

Stakeholder Impact

• Shareholders may observe the insider selling, but the pre-arranged nature of the 10b5-1 plan suggests it is part of a routine compensation strategy rather than a reaction to new company-specific information.

Key Dates

Recommendation

The filing reports a routine, pre-planned insider transaction (option exercise and sale) under a Rule 10b5-1 plan. While the officer realized a significant profit, this is a common practice for executive compensation and does not inherently signal a change in the company's fundamental outlook. Therefore, a 'hold' recommendation is appropriate as this event alone does not warrant a change in investment thesis.

Keywords

Maze Therapeutics, MAZE, Insider Trading, Form 4, Stock Sale, Option Exercise, Atul Dandekar, Rule 10b5-1